Hemogenyx Pharmaceuticals PLC Hemogenyx to present at Oxford conference (4816Z)
September 03 2018 - 2:00AM
UK Regulatory
TIDMHEMO
RNS Number : 4816Z
Hemogenyx Pharmaceuticals PLC
03 September 2018
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Hemogenyx to Present at the 'From Laboratory to Clinic'
Translational Research Conference in Oxford
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the Standard Listed
biopharmaceutical group developing new therapies and treatments
designed to transform bone marrow transplantation for the treatment
of blood diseases, announces that its CEO, Dr. Vladislav Sandler,
will present at the Kennedy Institute of Rheumatology conference
'From Laboratory to Clinic: Accelerating Experimental Medicine
Approaches' taking place at Trinity College, Oxford, from Tuesday 4
September until Friday 7 September 2018.
Dr. Sandler's presentation is entitled "Mouse-Human
Hematopoietic Chimeras for Disease Modelling and Drug Development"
and describes Hemogenyx's new platform technology that it uses as
an engine for novel product development. These novel humanized
mice, with a chimeric mouse-human blood system, are the subject of
a provisional patent application filing by the Company, as
announced in February 2018, and are being used as a tool for drug
development and testing, including in a collaboration with a major
US biotechnology company, and in a collaboration with The
Rockefeller University focused on auto-immune disease modelling to
develop new treatments for such diseases.
The Kennedy Institute of Rheumatology is part of the University
of Oxford's Nuffield Department of Orthopaedics, Rheumatology and
Musculoskeletal Science, which comprises more than 25 research
groups working in the areas of immunity and microbiome,
inflammation biology and tissue re-modelling/regeneration.
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer Via Walbrook PR
& Co-Founder
Sir Marc Feldmann, Executive Chairman
Optiva Securities Ltd Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey
Walbrook PR (UK Media & Investor Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com
Relations)
Paul McManus Mob: +44 (0)7980 541 893
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249 or Lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals PLC. is a publicly traded company
(LSE: HEMO) headquartered in London, with its wholly owned US
operating subsidiary, Hemogenyx LLC, located in Brooklyn, New York
at its state- of- the- art research facility ("Hemogenyx").
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risk of toxicity and death that are associated with bone marrow
transplantation, however, have meant that the procedure is used
only as a last resort and its use is restricted. Hemogenyx's
technology has the potential to enable many more patients suffering
from devastating blood diseases, such as leukemia and lymphoma, as
well as severe autoimmune diseases, such as multiple sclerosis,
aplastic anemia and systemic lupus erythematosus (Lupus), to
benefit from bone marrow transplantation.
Hemogenyx is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx is developing two distinct and complementary products, as
well as a platform technology that it uses as an engine for novel
product development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCUAONRWAAWOAR
(END) Dow Jones Newswires
September 03, 2018 02:00 ET (06:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2023 to Apr 2024